نوع مقاله : مقاله پژوهشی
نویسندگان
1 دانشیارگروه ایمونولوژی، دانشکده پزشکی، دانشگاه علوم پزشکی سبزوار، سبزوار، ایران
2 دانشجوی پزشکی، کمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی سبزوار، سبزوار، ایران
3 دانشجوی دکتری تخصصی، دانشکده پرستاری، دانشکده علوم بهداشت، دانشگاه اتاوا، اتاوا، ON، کانادا
4 متخصص پوست، گروه پوست، دانشکده پزشکی، دانشگاه علوم پزشکی سبزوار، سبزوار، ایران
5 دکتری تخصصی پژوهشی ایمونولوژی، مرکز تحقیقات سلولی و مولکولی، دانشگاه علوم پزشکی سبزوار، سبزوار، ایران
چکیده
زمینه و هدف: پسوریازیس یک بیماری پوستی شایع است که با پاپولها و پلاکهای پوسته پوسته ظاهر میشود و میتواند عواقب روانی و جسمی داشته باشد. با توجه به نقش ضدالتهابی ویتامین D، مطالعاتی در مورد ارتباط سطح سرمی این ویتامین با پسوریازیس انجام شدهاست. این مطالعه با هدف بررسی رابطه بین سطوح سرمی 25 هیدروکسی ویتامین D و پسوریازیس انجام شد.
مواد و روشها: این مطالعه مورد شاهدی بر روی بیماران پسوریازیس از کلینیک پوست بیمارستان واسعی و افراد سالم از مرکز انتقال خون سبزوار در ایران انجام شد. بیماران مبتلا به پسوریازیس مزمن (بیش از 6 ماه) در سنین 18 تا 65 سال بدون توجه به نوع پسوریازیس وارد مطالعه شدند. حجم نمونه این پژوهش 177 نفر (88 مورد و 89 گروه شاهد) بود. روش جمع‌آوری داده‌ها پرسش‌نامه و نمونه خون بود. در هر دو گروه، میزان 25 هیدروکسی ویتامین D به روش الایزا اندازه‌گیری شد.
یافتهها: 177 نفر شامل 78 نفر (44/10درصد) مرد و 99 نفر (55/90درصد) زن وارد این مطالعه شدند. میانگین سنی در گروه مورد 13/30±36/95و در گروه شاهد 12/60±21/34سال بود. میانگین سطوح ویتامین D بین گروه مورد (13/60±19/68) و گروه شاهد (12/60±21/34) تفاوت معنی‌داری نداشت (0/05>P).
نتیجه‌گیری: یافته‌های این مطالعه نشان داد که تفاوت معنی‌داری در سطوح ویتامین D بین گروه مورد و گروه کنترل وجود ندارد که این فرضیه که کمبود ویتامین D با پسوریازیس مرتبط است را تأیید نمی‌کند
تازه های تحقیق
https://pubmed.ncbi.nlm.nih.gov/?term=Mojadadi,+Mohammad+Shafi%5bAuthor%5d&sort=date
https://scholar.google.com/citations?hl=en&user=lBfBEnIAAAAJ&view_op=list_works&sortby=pubdate
https://scholar.google.com/citations?user=9RyPrEoAAAAJ&hl=en&authuser=1
https://pubmed.ncbi.nlm.nih.gov/?term=Amirpour,+Maryam%5bAuthor%5d
https://scholar.google.com/citations?user=xEn-dFUAAAAJ&hl=en&oi=ao
https://pubmed.ncbi.nlm.nih.gov/?term=Sahebkar,+Mohammad%5bAuthor%5d
https://scholar.google.com/citations?view_op=list_works&hl=en&user=9WfGs7EAAAAJ
https://pubmed.ncbi.nlm.nih.gov/?term=Karrabi,+Maryam%5bAuthor%5d
https://scholar.google.com/citations?user=NnuulHIAAAAJ&hl=en
https://pubmed.ncbi.nlm.nih.gov/?term=Shobeiri,+Saeideh+sadat%5bAuthor%5d
کلیدواژه‌ها
موضوعات
عنوان مقاله [English]
Relationship Between Serum 25-Hydroxy-Vitamin D Levels and Psoriasis: A Case-Control Study
نویسندگان [English]
- Mohammad Shafi Mojadadi 1
- Maryam Amirpour 2
- Mohammad Sahebkar 3
- Maryam Karrabi 4
- saeideh sadat shobeiri 5
1 Associate Professor, Department of Immunology, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.
2 MD student, Student Research committee, Sabzevar University of Medical Sciences, Sabzevar, Iran.
3 PhD student, School of Nursing, Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada.
4 Dermatologist, Department of Dermatology, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.
5 PhD of Immunology, Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
چکیده [English]
Introduction: Psoriasis is a common skin disease that presents with papulosquamous lesions (scaly papules and plaques) and can have psychological and physical consequences. Due to the anti-inflammatory role of vitamin D, studies have been conducted on the relationship between serum levels of this vitamin and psoriasis. In recent years, conflicting results have been obtained, all of which emphasize the importance of investigating this issue. This study aimed to investigate the relationship between serum 25-hydroxy-vitamin D levels and psoriasis.
Materials and Methods: We conducted a case-control study with psoriasis patients from Vasei Hospital's dermatology clinic and healthy people from Sabzevar Blood Transfusion Center in Iran. Patients with chronic psoriasis (more than 6 months) aged 18 to 65 years were included in the study regardless of the type of psoriasis. This study had a sample size of 177 people (88 cases, and 89 controls). The data collection methods were a questionnaire and blood samples. In both groups, the amount of 25-hydroxy-vitamin D was measured by ELISA method.
Results: This study recruited 177 individuals: 78 (44.10%) males and 99 (55.90%) females. The mean age in the case group was 36.95±13.30 and in the control group, it was 21.34±12.60 years. The mean vitamin D levels had no significant difference between the case (19.68±13.60) and the control groups (21.34±12.60) (P>0.05).
Conclusion: The findings of this study showed that there was no significant difference in vitamin D levels between the case group and the control group, which did not support the hypothesis that vitamin D deficiency is associated with psoriasis.
کلیدواژه‌ها [English]
- Psoriasis
- Vitamin D
- Dermatology
- 25-hydroxy vitamin D
- Inflammation
- Shobeiri SS, Khorrami M, Sankian M. Plaque-type psoriasis inhibitors. International Immunopharmacology. 2021;101:108326. DOI:1016/j.intimp.2021.108326.
- Banaszczyk K. Risankizumab in the treatment of psoriasis–literature review. Reumatologia. 2019;57(3):158. DOI: https://doi.org/10.5114/reum.2019.86426.
- Claudia C-D, María-Elena V-H, Josué V-E, María-Carmen B-C, Alain-Raimundo R-O, Martha-Estrella G-P. Small molecules under development for psoriasis: on the road to the individualized therapies. Archives of Dermatological Research. 2020;312(9):611-27. DOI: https://doi.org/10.1007/s00403-020-02056-3.
- Lopes N, Dias LL, Azulay-Abulafia L, Oyafuso LK, Suarez MV, Fabricio L, et al. Humanistic and economic impact of moderate to severe plaque psoriasis in Brazil. Advances in therapy. 2019;36(10):2849-65. DOI: https://doi.org/10.1007/s12325-019-01049-7.
- Feldman SR, Goffe B, Rice G, Mitchell M, Kaur M, Robertson D, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. American health & drug benefits. 2016;9(9):504.
- Kromer C, Celis D, Sonntag D, Peitsch WK. Biologicals and small molecules in psoriasis: A systematic review of economic evaluations. PloS one. 2018;13(1):e0189765. DOI: https://doi.org/10.1371/journal.pone.0189765.
- Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA dermatology. 2015;151(6):651-8. DOI: 10.1001/jamadermatol.2014.3593.
- Tambe VS, Nautiyal A, Wairkar S. Topical lipid nanocarriers for management of psoriasis-an overview. Journal of Drug Delivery Science and Technology. 2021;64:102671. DOI: https://doi.org/10.1016/j.jddst.2021.102671.
- Kim BY, Choi JW, Kim BR, Youn SW. Histopathological findings are associated with the clinical types of psoriasis but not with the corresponding lesional psoriasis severity index. Annals of dermatology. 2015;27(1):26-31. DOI: https://doi.org/10.5021/ad.2015.27.1.26.
- Shobeiri SS, Rezaee M, Pordel S, Haghnnavaz N, Dashti M, Moghadam M, et al. Anti-IL-17A ssDNA aptamer ameliorated psoriasis skin lesions in the imiquimod-induced psoriasis mouse model. International Immunopharmacology. 2022;110:108963. DOI: 10.1016/j.intimp.2022.108963.
- Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. Journal of the American Academy of Dermatology. 2004;50(6):859-66. Epub 2004/05/22. DOI: 10.1016/j.jaad.2003.09.014.
- AlRuthia Y, Alfakhri AH, Alharbi I, Alghamdi FA, Alanazi MA, Alrabiah AA, et al. Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia. Cost Effectiveness and Resource Allocation. 2023;21(1):95. DOI: 10.1186/s12962-023-00504-1.
- Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. International journal of experimental pathology. 2009;90(3):232-48. DOI: 1111/j.1365-2613.2009.00669.x.
- Le P, Tu J, Gebauer K, Brown S. Serum 25‐hydroxyvitamin D increases with NB‐UVB and UVA/UVB phototherapy in patients with psoriasis and atopic dermatitis in W estern A ustralia. Australasian Journal of Dermatology. 2016;57(2):115-21. DOI: https://doi.org/10.1111/ajd.12315.
- Franken SM, Witte B, Pavel S, Rustemeyer T. Psoriasis and daily low‐emission phototherapy: effects on disease and vitamin D level. Photodermatology, Photoimmunology & Photomedicine. 2015;31(2):83-9. DOI: 1111/phpp.12151.
- Mason AR, Mason JM, Cork MJ, Hancock H, Dooley G. Topical treatments for chronic plaque psoriasis of the scalp: a systematic review. The British journal of dermatology. 2013;169(3):519-27. Epub 2013/06/26. DOI: 10.1111/bjd.12393.
- Bikle DD. Vitamin D and the skin: Physiology and pathophysiology. Reviews in Endocrine and Metabolic Disorders. 2012;13(1):3-19. DOI: 1007/s11154-011-9194-0.
- Coussens AK. The role of UV radiation and vitamin D in the seasonality and outcomes of infectious disease. Photochemical & Photobiological Sciences. 2017;16(3):314-38. DOI: https://doi.org/10.1039/C6PP00355A .
- Gisondi P, Rossini M, Di Cesare A, Idolazzi L, Farina S, Beltrami G, et al. Vitamin D status in patients with chronic plaque psoriasis. British Journal of Dermatology. 2012;166(3):505-10. DOI: 1111/j.1365-2133.2011.10699.x.
- Fu LW, Vender R. Systemic role for vitamin D in the treatment of psoriasis and metabolic syndrome. Dermatology research and practice. 2011;2011. DOI: 1155/2011/276079.
- Kılıç S, Sılan F, Hız M, Işık S, Ögretmen Z, Özdemir Ö. Vitamin D receptor gene BSMI, FOKI, APAI, and TAQI polymorphisms and the risk of atopic dermatitis. Journal of investigational allergology & clinical immunology. 2016;26(2):106-10. DOI: 18176/jiaci.0020.
- Schlager J, Rosumeck S, Werner R, Jacobs A, Schmitt J, Schlager C, et al. Topical treatments for scalp psoriasis: summary of a Cochrane Systematic Review. British Journal of Dermatology. 2017;176(3):604-14. DOI: 1111/bjd.14811.
- Upala S, Sanguankeo A. Low 25‐hydroxyvitamin D levels are associated with vitiligo: a systematic review and meta‐ Photodermatology, photoimmunology & photomedicine. 2016;32(4):181-90. DOI: 10.1111/phpp.12241.
- Giuggioli D, Colaci M, Cassone G, Fallahi P, Lumetti F, Spinella A, et al. Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature. Clinical rheumatology. 2017;36(3):583-90. DOI: 1007/s10067-016-3535-z.
- Aksu Cerman A, Sarikaya Solak S, Kivanc Altunay I. Vitamin D deficiency in alopecia areata. British Journal of Dermatology. 2014;170(6):1299-304.DOI: 1111/bjd.12980.
- Mok C, Birmingham D, Ho L, Hebert L, Song H, Rovin B. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus. 2012;21(1):36-42.DOI: 1177/0961203311422094.
- Muehleisen B, Bikle DD, Aguilera C, Burton DW, Sen GL, Deftos LJ, et al. PTH/PTHrP and vitamin D control antimicrobial peptide expression and susceptibility to bacterial skin infection. Science translational medicine. 2012;4(135):135ra66-ra66. DOI: 1126/scitranslmed.3003759.
- Lee YH, Song GG. Association between circulating 25-hydroxyvitamin D levels and psoriasis, and correlation with disease severity: a meta-analysis. Clinical and experimental dermatology. 2018;43(5):529-35. Epub 2018/01/18. DOI: 10.1111/ced.13381.
- Zuchi MF, Azevedo PdO, Tanaka AA, Schmitt JV, Martins LEAM. Serum levels of 25-hydroxy vitamin D in psoriatic patients. Anais brasileiros de dermatologia. 2015;90:430-2. DOI: 1590/abd1806-4841.20153524.
- Maleki M, Nahidi Y, Azizahari S, Meibodi NT, Hadianfar A. Serum 25-OH vitamin D level in psoriatic patients and comparison with control subjects. Journal of cutaneous medicine and surgery. 2016;20(3):207-10. DOI: 1177/1203475415622207.
- Barrea L, Savanelli MC, Di Somma C, Napolitano M, Megna M, Colao A, et al. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Reviews in endocrine & metabolic disorders. 2017;18(2):195-205. Epub 2017/02/09. DOI: 10.1007/s11154-017-9411-6.
- Li L, Wu X, Wu J, Zhang X, Miao F, Wang J, et al. Transdermal delivery of Fn14 siRNA using a novel composite ionic liquid for treatment of psoriasis-like skin lesions. Journal of Controlled Release. 2024;365:818-32. DOI: https://doi.org/10.1016/j.jconrel.2023.12.009.
- Calton EK, Keane KN, Newsholme P, Soares MJ. The Impact of Vitamin D Levels on Inflammatory Status: A Systematic Review of Immune Cell Studies. PloS one. 2015;10(11):e0141770. Epub 2015/11/04. DOI: 10.1371/journal.pone.0141770.
- Mattozzi C, Paolino G, Richetta AG, Calvieri S. Psoriasis, vitamin D and the importance of the cutaneous barrier's integrity: An update. The Journal of dermatology. 2016;43(5):507-14. Epub 2016/03/15. DOI: 10.1111/1346-8138.13305.
- Solak B, Dikicier BS, Celik HD, Erdem T. Bone Mineral Density, 25-OH Vitamin D and Inflammation in Patients with Psoriasis. Photodermatol Photoimmunol Photomed. 2016;32(3):153-60. Epub 2016/02/13. DOI: 10.1111/phpp.12239.
- Formisano E, Proietti E, Borgarelli C, Pisciotta L. Psoriasis and Vitamin D: A Systematic Review and Meta-Analysis. Nutrients. 2023;15(15):3387. DOI: 3390/nu15153387.
- Filoni A, Vestita M, Congedo M, Giudice G, Tafuri S, Bonamonte D. Association between psoriasis and vitamin D: Duration of disease correlates with decreased vitamin D serum levels: An observational case-control study. Medicine. 2018;97(25):e11185. Epub 2018/06/21. DOI: 10.1097/md.0000000000011185.
- Petho Z, Kulcsar-Jakab E, Kalina E, Balogh A, Pusztai A, Gulyas K, et al. Vitamin D status in men with psoriatic arthritis: a case-control study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2015;26(7):1965-70. Epub 2015/02/20. DOI: 10.1007/s00198-015-3069-2.
- Chandrashekar L, Kumarit GR, Rajappa M, Revathy G, Munisamy M, Thappa DM. 25-hydroxy vitamin D and ischaemia-modified albumin levels in psoriasis and their association with disease severity. British journal of biomedical science. 2015;72(2):56-60. Epub 2015/07/02. DOI: 10.1080/09674845.2015.11666797.
)